ArticlePDF Available

Abstract and Figures

Alcohol addiction is a worldwide problem. It has mainly two components: dependence and withdrawal. Characteristic properties of most anti-addictive compounds include anti-anxiety, anticonvulsant, antidepressant, and nootropic actions. Shankhpushpi (Convolvulus pluricaulis. Convolvulaceae), known ethnopharmacologically as brain tonic, possess all the properties mentioned above. Here, we screen shankhpushpi for possible anti-addictive potential. Effect of shankhpushpi churna was measured on ethanol withdrawal anxiety using elevated plus maze. The role of shankhpushpi on chronic ethanol consumption (21 days) was measured using two bottle choice protocol of voluntary drinking. We also measured the effect of the above herb on cortico-hippocampal GABA levels. Shankhpushpi was found to reduce alcohol withdrawal anxiety in a dose-dependent manner. The herb also decreased ethanol intake and increased water intake significantly (P < 0.001) after 4 days of administration. Both these effects were blocked (P < 0.001) by GABAA antagonist suggesting the role of GABAA receptor. Chronic administration of shankhpushpi also significantly (P < 0.01) increased cortico-hippocampal GABA levels in mice. Shankhpushpi reduced both alcohol dependence and withdrawal in a GABAA-dependent manner, thus showing anti-addictive potential. SUMMARY Shankhpushpi prevented ethanol withdrawal anxiety and alcohol addiction in a GABAA-dependent manner. Abbreviations used: GABA: Gamma-Aminobutyric Acid, HIV: Human Immunodeficiency Virus, CNS: Central Nervous System
Content may be subject to copyright.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
© 2016 Pharmacognosy Magazine|Published by Wolters Kluwer‑Medknow 1
This is an open access article distributed under the terms of the Creative Commons
Attribution‑Non Commercial‑Share Alike 3.0 License, which allows others to remix,
tweak, and build upon the work non‑commercially, as long as the author is credited
and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
Cite this article as: FPO
Submitted: 18‑08‑2016 Revised: 24‑10‑2016 Published: 00‑00‑0000
ABSTRACT
Alcohol addiction is a worldwide problem. It has mainly two components:
dependence and withdrawal. Characteristic properties of most anti-addictive
compounds include anti-anxiety, anticonvulsant, antidepressant, and
nootropic actions. Shankhpushpi (Convolvulus pluricaulis. Convolvulaceae),
known ethnopharmacologically as brain tonic, possess all the properties
mentioned above. Here, we screen shankhpushpi for possible anti-addictive
potential. Effect of shankhpushpi churna was measured on ethanol
withdrawal anxiety using elevated plus maze. The role of shankhpushpi
on chronic ethanol consumption (21 days) was measured using two bottle
choice protocol of voluntary drinking. We also measured the effect of
the above herb on cortico-hippocampal GABA levels. Shankhpushpi was
found to reduce alcohol withdrawal anxiety in a dose-dependent manner.
The herb also decreased ethanol intake and increased water intake
signicantly (P < 0.001) after 4 days of administration. Both these effects
were blocked (P < 0.001) by GABAA antagonist suggesting the role of
GABAA receptor. Chronic administration of shankhpushpi also signicantly
(P < 0.01) increased cortico-hippocampal GABA levels in mice. Shankhpushpi
reduced both alcohol dependence and withdrawal in a GABAA-dependent
manner, thus showing anti-addictive potential.
SUMMARY
Shankhpushpi prevented ethanol withdrawal anxiety and alcohol addiction in
a GABAA-dependent manner.
Eect of Shankhpushpi on Alcohol Addiction in Mice
Mahi Heba, Sana Faraz, Sugato Banerjee
Department of Pharmaceutical Science and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India
INTRODUCTION
Alcohol addiction is a worldwide problem. Alcohol consumption
accounts for more than 3.3 and is the h leading risk factor for
premature death and disability. Alcohol contributes various diseases and
injury-related health conditions, most notably alcohol dependence, liver
cirrhosis, cancers, HIV, and injuries, primarily road trac accidents.[1,2]
Alcohol dependence is a complex and dynamic process involving
various neurobiologic and environmental factors.[3] Individuals
propensity to alcohol consumption is primarily a balance between
alcohol’s rewarding eects and its withdrawal consequences. One
factor contributing to relapse is withdrawal related anxiety, which
likely reects adaptive changes in the brain in response to continued
alcohol exposure. Association of these pleasant/unpleasant feelings with
environmental clues may inuence alcohol intake.[4] Alcohol withdrawal
symptoms include irritability, agitation, anxiety, sleep disturbances,
and reduced pain threshold both in human and animals.[5] Disulram,
naltrexone, and acamprosate are US Food and Drug Administration
(US-FDA) approved medications for treatment of alcohol dependence.
However, they have various side eects including palpitation, ushing,
nausea, vomiting, headache, anxiety, sedation, and transient diarrhea,
which aect the quality of life of the addicted individual under
anti-addictive therapy.
Herbal medicines can be used for the development of new therapeutically
active compounds with higher potency and lower toxicity. Most modern
drugs have a natural origin and play a major role in drug development.[6]
Shankhpushpi (Convolvulus pluricaulis Choisy) is a perennial herb
referred to as morning glory. e plant is used locally in Indian and
Chinese system of medicine to treat various diseases. Its dierent
pharmacologic actions include cough suppressant, antihypertensive,
antiulcer, hypolipidemic, and against various neurologic disorders. It
may be used as a stress reliever, a mood stabilizer, and memory enhancer.
It may also reduce peripheral nerve hyperexcitability, as well as used as an
adjuvant to anticonvulsant therapy.[7,8] Its primary chemical constituent
pm_376_16
Key words: Alcohol, addiction, Convolvulus pluricaulis, shankhpushpi,
mice Correspondence:
Dr. Sugato Banerjee,
Department of Pharmaceutical Sciences and
Technology, Birla Institute of Technology,
Mesra, Ranchi, Jharkhand, India.
E-mail: sbanerjee@bitmesra.ac.in
Pharmacogn. Mag.
A multifaceted peer r
eviewed journal in the  eld of Pharmacognosy and Natural Products
www
.phcog.com|www.phcog.net
Abbreviations used: GABA: Gamma-Aminobutyric Acid, HIV: Human
Immunodeciency Virus, CNS: Central Nervous System
ORIGINAL ARTICLE
MAHI HEBA, et al.: Eect of Shankhpushpi on Alcohol Addiction
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
2 Pharmacognosy Magazine, Apr‑Jun 0000, Vol 00, Issue 00 (Supplement 2)
includes alkaloids like shankhpushpine, convolamine, convoline,
convolidine, convolvine, confoline, convosine, and so on, found in
dierent species from this family. e fresh plant contains volatile oils,
fatty acids, fatty alcohols, and hydrocarbons like myristic acid, palmitic
acid, linoleic acid, and straight-chain hydrocarbons like hextriacontane.
e avonoid kampferol and steroids phytosterol, β-sitosterol have also
been extracted.[7,9] Many of these active constituents isolated from aerial
parts of C. pluricaulisy like shankhpushpine, scopoletin, kaempferol
phytosterol, and β-sitosterol have been shown to act as GABAA agonists,
which could be attributed to the anxiolytic and CNS-depressant actions
of shankhpushpi.[10]
Here, we report that acute administration of shankhpushpi may
prevent alcohol withdrawal anxiety, whereas its chronic administration
may reduce alcohol consumption in mice. Chronic administration of
shankhpushpi extract led to change in cortico-hippocampal GABA
levels, whereas GABAA blocker completely reversed its anti-addictive
properties. us, above results suggest that C. pluricaulis may prevent
alcohol addiction in a GABAA-dependent manner.
MATERIALS AND METHODS
Animals
Swiss albino mice (20–30 g) were used in this study. Animals were issued
from the Institutional Animal House (Reg. No. 621/02/AC/CPCSEA) of
Birla Institute of Technology, Mesra. All animals were kept in polyacrylic
cages and maintained under standard conditions (room temperature
24–27°C and humidity 60–65% with 12:12 light:dark cycles). e food
was provided in the form of dry pellets and water ad libitum. e animals
were allowed to get acclimatized to the laboratory conditions for 7 days
before the commencement of the experiment. All experiments involving
animals complied with the ethical standards of animal handling and
approved by the Institutional Animal Ethics Committee (BIT/PH/
IAEC/28/2013).
Estimation of blood alcohol levels
Blood was collected by retro-orbital bleeding with animals in light ether
anesthesia aer 20 min of ethanol administration. Ethanol levels were
measured using ultraviolet (UV) assay kit for alcohol estimation based
on manufacturer’s protocol (NZY Tech Genes and Enzymes Portugal).
Development of conditioned place preference
model
Apparatus
e conditioned place preference (CPP) apparatus contain three
compartments. e two end compartments (30.5 cm × 26.5 cm × 37 cm)
were connected by a central corridor (12.75 cm × 23 cm × 15.25 cm). e
compartment on the le had black walls with a perforated stainless steel
oor with round holes on staggered centers. e central corridor was
transparent with a smooth plexiglass oor, and the right compartment
had white walls with a stainless steel mesh oor.
CPP was performed as described previously,[11,12] with slight modications.
It mainly consists of three phases:
(1) Preconditioning phase: (rst and second day) e animals were
placed in the middle chamber and allowed to explore both the chambers
for 30 min.
(2) Conditioning phase: (3rd - 10th day) Each mouse was treated for eight
consecutive sessions with the alternate oral administration of alcohol
and saline. On days 3, 5, 7, and 9, the animals were administered ethanol
(2 g/kg body weight; i.p. 10% [v/v]) and placed in one compartment for
30 min. Besides, on days 4, 6, 8, and 10, the animals were administered
saline and placed in opposite compartment.
(3) Postconditioning phase: (11th–12th day) Mice were placed in the
middle chamber and allowed free access to both chambers for 30 min.
Time spent in ethanol and saline-paired chamber was measured.
(4) Treatment protocol: Aer development of withdrawal (15th day), the
following treatment schedule was followed:
Group 1: saline
Group 2: ethanol
Group 3: ethanol + shankhpushpi (Vyas Pharmaceuticals, Haridwar; 100
mg/kg)
Group 4: ethanol + shankhpushpi (200 mg/kg)
Group 5: ethanol + diazepam (1 mg/kg)
Group 6: ethanol + GABAA antagonist
Group 7: ethanol + GABAB agonist
Group 8: ethanol + shankhpushpi + GABAA antagonist
Group 9: ethanol + shankhpushpi + GABAB agonist
e behavioral tests were performed 60 min aer oral drug administration
and 30 min aer intraperitoneal administration.
Behavioral studies to measure alcohol withdrawal
anxiety
Elevated plus maze
e model has been validated pharmacologically and currently
considered the “gold standard” test of anxiety-related behavior. Elevated
plus maze (EPM) was performed as described by Kokare et al.[13] In
summary, aer drug treatment, individual mice were placed at the center
of the maze, head facing an open arm. During the 5 min test period,
the number of entries and time spent on the open arm were recorded
automatically (Medicra Electromedical, Lucknow, India).
Chronic‑treatment study to measure alcohol intake
Two‑bottle choice ethanol drinking
We used the standard two-bottle choice protocol, which is a widely used
animal model to capture aspects of voluntary alcohol consumption in
humans.[14] Following 7 days of acclimatization, animals were subjected
to an ethanol drinking acquisition regimen. e animals remained in
their home cages at all times throughout the study but had their water
bottles removed during a 4 h and ethanol presentation period. During this
time, animals were exposed to a free choice between ethanol (15% v/v)
and water for 20 days but with no drug pretreatment.
Aer 20 days of ethanol administration, animals were divided into
dierent groups for 10 days of treatment. Each day, the bottles were
weighed before and aer 4 h of limited access period and the dierences
were used to calculate the water and ethanol intake. e mean intake was
expressed as g/kg body weight/day of water and g/ kg body weight/day of
ethanol intake. All animals were given unrestricted food access. Every 2
days, the bottles were switched to eliminate place preference.[15] Aer 20
days of pretreatment with ethanol (15% v/v), the animals were divided
into dierent treatment groups (n = 7 per group) as follows:
Group 1: (control) received saline 30 days
Group 2: received free choice ethanol (15% v/v)/water 30 days
Group 3: received free choice ethanol (15% v/v)/water and shankhpushpi
(200 mg/kg) 21st–30th day
Group 4: received free choice ethanol (15% v/v)/water and diazepam
21st–30th day.
Group 5: received free choice ethanol (15% v/v)/water, GABAA antagonist
and shankhpushpi 21st–30th day.
(Thermo Fisher Scientific (India) Pvt. Ltd)
MAHI HEBA, et al.: Eect of Shankhpushpi on Alcohol Addiction
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
Pharmacognosy Magazine, Apr‑Jun 0000, Vol 00, Issue 00 (Supplement 2) 3
Aer the above experimental protocol of 30 days, ve animals per
group were sacriced under ether anesthesia by cervical dislocation for
biochemical estimation.
Estimation of gamma amino butyric acid levels from brain tissue
Brain tissue was homogenized in 5 mL of 0.01 M HCl. In this homogenate,
8 mL of ice cold ethanol was added and kept for 1 h at 0°C. e contents
were centrifuged for 10 min at 16,000 rpm and supernatant was collected
in a petri dish. e precipitate was washed three times with 5 mL of 75%
ethanol. e washes were combined with supernatant and evaporated
to dryness. To the dry mass, 1 mL water and 2 mL chloroform were
added and centrifuged at 2000 rpm. Upper phase containing GABA was
separated, and 10 μL of it was applied as spot on Whatman lter paper.
e mobile phase consisted of n-butanol, acetic acid, and water in 4:1:5
ratios. e chamber was saturated for half an hour with mobile phase.
e paper chromatogram was developed with ascending technique. e
paper was dried in a hot air oven and then sprayed with 0.5% ninhydrin
solution in 95% ethanol. e paper was dried. Blue spot developed on
paper, which was cut and heated with 2 mL ninhydrin solution on a
water bath at 60–65°C. Water was added to the solution and kept for 1
h and supernatant was used. Absorbance was measured at 570 nm on a
UV-visible spectrophotometer.
RESULTS
CPP
In CPP, the animal’s choice to spend more time in either environment
provides a direct measure of the conditioned reinforcing eect of a
drug. Animals were found to prefer the ethanol-paired chamber over
the saline-paired chamber. In our study on day 11, the ethanol-treated
animals spent signicantly more time in the ethanol-paired chamber
as compared to the saline-paired chamber (P < 0.001). Animals
spent about 66% of total time in ethanol-paired chamber versus the
saline-paired. For the control group (saline-treated), the time spent in
both the chambers were comparable [Figure 1]. Similar results were
observed on day 12 (data not shown). e CPP results suggested that the
animals got addicted to alcohol. Ethanol levels in the blood samples were
found to be 47 mg/dL (n = 6).
Eect of shankhpushpi on withdrawal anxiety
In the present study, according to the CPP model described by anos
et al.,[11] with minor modications, acute ethanol withdrawal anxiety
was developed and measured using elevated plus maze test. Five days
of abstinence followed 10 days of conditioning phase in which alternate
dose of ethanol and saline was given for 10 days. Aer 5 days of abstinence
from ethanol, animals showed a signicant decrease in time spent
(P < 0.01) in the open arm of the elevated plus maze as compared with the
control, suggesting withdrawal anxiety. Shankhpushpi (100 and 200 mg/kg)
administration led to a dose-dependent reversal of withdrawal anxiety
as evidenced by signicant increase in time spent in the open arm
(P < 0.01).
Both 200 mg/kg shankhpushpi and diazepam showed comparable
anxiolytic potential against ethanol withdrawal anxiety. However,
pretreatment with GABAA antagonist prevented shankhpushpi-mediated
reversal of withdrawal anxiety (P < 0.001) [Figure 2]. Treatment with
GABAB agonist and shankhpushpi did not show any signicant change
in withdrawal anxiety compared with shankhpushpi-treated animals
(data not shown). e above results suggest that shankhpushpi may
Figure 1: CPP on ethanol administration. Time spent in alcohol and saline
administration chamber on day 11 by control and ethanol‑treated group.
Ethanol‑treated animals showed signicant increase in (P < 0.001) time
spent in ethanol‑paired alcohol compared with saline‑paired chamber.
Values represent mean ± standard error of the mean n = 7
Figure 2: Eect of shankhpushpi on ethanol withdrawal anxiety using
elevated plus maze. Ethanol abstinence signicantly decreased (P < 0.001)
time spend in open arm compared with ethanol‑treated animals.
Shankhpushpi treatment to abstinent animals signicantly (100 mg/kg,
P < 0.01 and 200 mg/kg, P < 0.001) increased time spend in open arm
compared with abstinent animals. Diazepam also signicantly increased
time spend in open arm over abstinent and ethanol‑treated groups
(P < 0.001). Animals treated with shankhpushpi in the presence of GABAA
spent signicantly less time in the open arm (P < 0.001) compared with
abstinent animals.
MAHI HEBA, et al.: Eect of Shankhpushpi on Alcohol Addiction
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
4 Pharmacognosy Magazine, Apr‑Jun 0000, Vol 00, Issue 00 (Supplement 2)
chamber, thus conrming the development of addiction. Ethanol
consumption followed by withdrawal results in the development of
abstinence syndrome.[14–18] Common and prominent feature of alcohol
withdrawal is anxiety, which is also considered to be the most important
negative motivation to revert to alcohol use.[19] e above sign of ethanol
withdrawal (EW) have been attributed to upregulation of NMDA
receptors[20] and downregulation of GABAA receptors.[21] erefore, a
drug that either facilitates the action of GABA or decreases glutamate
activity may be eective in EW-induced anxiety behavior. e elevated
plus maze is the most commonly employed tests for assessing anxiety-
like behavior aer alcohol withdrawal, which is a measure of psychologic
dependency.[22] Typical anxiolytic drugs increase the proportion of
entries, time spent, and rearing in the open arms. e anxiolytic potential
of shankhpushpi churna and diazepam were studied on acute ethanol
withdrawal anxiety using elevated plus maze. Abstinence to ethanol
led to precipitation of withdrawal anxiety as revealed by the signicant
reduction in time spent in open arm of EPM. Shankhpushpi churna and
diazepam increased the time spent in open arm, thus reducing ethanol
withdrawal anxiety, one of the primary reasons for alcohol addiction.
Benzodiazepines are a positive allosteric modulator of GABAA. ey
act by potentiating the eect of GABA on its receptor.[23] It has been
suggested that downregulation of GABAA receptor and/or decrease in
the GABAergic transmission may be responsible for ethanol withdrawal.
Diazepam acts by potentiating the eect of GABA at the receptor site
and shows its anxiolytic property. We also found a signicant increase
in GABA levels upon administration of shankhpushpi churna and
diazepam. Treating animals with GABAA antagonist successfully
reversed the anxiolytic property of shankhpushpi, thus pointing toward
the role of GABAA receptor in shankhpushpi-mediated reduction in
withdrawal anxiety.
Next, we determined the eect of shankhpushpi on alcohol consumption
in mice. e two-bottle choice protocol is a widely used model that
captures aspects of voluntary alcohol consumption in humans.[24] Aer
30 days of chronic ethanol intake, animals showed increased cortico-
hippocampal levels of GABA as we reported previously.[25] Decrease
in GABAergic function aer chronic administration of alcohol in
experimental animals has been widely attributed to decrease in
GABAA receptor expression and function.[26] Shankhpushpi treatment
signicantly increased GABA levels in the cortico-hippocampal lysates
over ethanol-treated animals. Diazepam, a standard anxiolytic drug also
showed increased GABA levels. Others have also reported the role of
GABA in anxiolytic property of aerial parts of C. pluricaulis.[27] Alcohol
is an indirect GABA agonist. Plasma and CSF level of GABA have been
found to remain high aer initial withdrawal than aer longer periods of
abstinence.[28] Evidence showed a decrease in GABAergic function aer
chronic administration of alcohol in experimental animals, which has
been attributed to decrease in the GABAA receptors or changes in the
composition of the receptor.[26]
Ethanol intake by mice was found to increase till the 20th day. Aer day
24, there was a signicant decrease in ethanol intake and increase in
water intake for shankhpushpi and diazepam, treated animal which was
completely blocked upon administration of GABAA blocker e above
results suggest that shankhpushpi may prevent ethanol intake in a GABAA-
dependent manner. Alcohol’s action on GABAA receptors strongly
depends on its subunit composition. GABAA receptors are composed of
α, β, γ, and δ subunits forming a pentameric ligand-gated ion channel
receptor. While most subunit compositions of GABAA receptors display
responses to alcohol only at high concentrations (460 mM), it has been
found that lower concentrations (1—3 mM) of alcohol may only alter
the activity the δ subunit.[29] Pharmacologic manipulation of GABAA
receptors has been studied in mice. Negative allosteric modulators of
reverse ethanol withdrawal anxiety in a GABAA-dependent manner.
Eect of shankhpushpi on cortico‑hippocampal
GABA levels
Aer 30 days of alcohol treatment, animals showed a signicant increase
(P < 0.01, n = 5) in cortico-hippocampal GABA as compared with
control group. Shankhpushpi (200 mg/kg) treatment (10 days) showed a
signicant (P < 0.01, n = 5) increase in GABA as compared with alcohol-
consuming animals. is signicance further increased (P < 0.001, n = 5)
in diazepam-treated group as compared with alcohol group [Figure 3].
Eect of shankhpushpi on alcohol consumption
Shankhpushpi-treated animals showed a signicant (P < 0.001, n = 7)
decrease in ethanol and water intake as compared with the control group
aer day 24 or 4 days postshankhpushpi therapy. is was comparable
with diazepam-treated animals, who also showed a signicant decrease
(P < 0.001, n = 7) in ethanol intake. However, animals’ administration
with GABAA blocker followed by shankhpushpi failed to show a decrease
in ethanol and increase in water intake till day 30. e above results
suggest that shankhpushpi prevented chronic ethanol intake, which may
be mediated by GABAA receptors [Figure 4].
DISCUSSION
In the present work, we study the eect of shankhpushpi in both acute
alcohol withdrawal and chronic alcoholism. Addiction model used in
the alcohol-withdrawal study was CPP. e CPP results suggest that
when given a choice aer administration of alcohol for 11 days, the
animals preferred the ethanol-paired chamber to that of saline-paired
Figure 3: Eect of shankhpushpi on cortico‑hippocampal GABA levels.
Shankhpushpi (200 mg/kg) treatment (10 days) led to signicant increase
(P < 0.01) in cortico‑hippocampal GABA levels compared with untreated
animals on ethanol (30 days). Diazepam treatment also showed a
signicant increase (P < 0.001) increase in cortico‑hippocampal gamma
amino butyric acid levels. Values represent mean ± standard error of the
mean n = 5
MAHI HEBA, et al.: Eect of Shankhpushpi on Alcohol Addiction
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
Pharmacognosy Magazine, Apr‑Jun 0000, Vol 00, Issue 00 (Supplement 2) 5
Figure 4: Eect of shankhpushpi on ethanol intake. (a) Changes in the ethanol intake before and after treatment. Shankhpushpi‑ and diazepam‑treated
animals showed a signicant decrease in ethanol intake compared with untreated ethanol consuming animals from day 24 (P < 0.001, n = 7) or after 4 days of
treatment. In presence of GABAA blocker shankhpushpi showed little decrease in (P > 0.5) ethanol intake compared with ethanol‑consuming animals till day
30. (b) Changes in ethanol intake on day 24 of the 30 days study. All treatment groups other than GABAA blocker + shankhpushpi group showed signicant
(P < 0.001) decrease in alcohol intake. (c) Change in the water intake before and after treatment. Shankhpushpi (200 mg/kg) and diazepam‑treated animals
showed a signicant increase in water intake compared with untreated ethanol‑consuming animals from day 24 (P < 0.001, n = 7) or after 4 days of treatment.
In presence of GABAA blocker shankhpushpi did not show an increase (P > 0.5) in water intake compared with ethanol‑consuming animals. (d) Change in
alcohol intake on day 24 of the 30 days study. All treatment groups other than GABAA blocker + shankhpushpi group showed signicant (P < 0.001) increase
in water intake. Values represent mean ± standard error of the mean, n = 7
MAHI HEBA, et al.: Eect of Shankhpushpi on Alcohol Addiction
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
6 Pharmacognosy Magazine, Apr‑Jun 0000, Vol 00, Issue 00 (Supplement 2)
12. Juan CL, Laura F, Pablo B. Modulation of ethanol-induced conditioned place preference in
mice by 3-amino-1,2,4-triazole and D-penicillamine depends on ethanol dose and number of
conditioning trials. Psychopharmacology 2013;230:557-68.
13. Kokare DM, Chopde CT, Subhedar NK. Participation of alpha-melanocyte stimulating
hormone in ethanol-induced anxiolysis and withdrawal anxiety in rats. Neuropharmacology
2006;51:536-
14. Li TK. Pharmacogenetics of responses to alcohol and genes that inuence alcohol drinking.
J Stud Alcohol 2000;61:5-12.
15. Marcucella H. Predicting the amount of ethanol consumed per bout from schedule of access
to ethanol. Anim Learn Behav 1989;17:101-2.
16. Hall W, Zador D. The alcohol withdrawal syndrome. Lancet 1997;349:1897-900.
1 7. Anton RF, Becker HC. Pharmacotherapy and pathophysiology of alcohol withdrawal. Alcohol
Res Health 1997;24:315-67.
18. Becker HC. Animal models of alcohol withdrawal. Alcohol Res Health 2000;24:105-13.
19. Kliethermes CL. Anxiety-like behaviors following chronic ethanol exposure. Neurosci
Biobehav Rev 2005;28:837.
20. Draski L, Deitich RA. Pharmacological effects of ethanol on nervous system. Alcohol Res
Health 1995;24:227-50.
21. Hunt WA. Alcohol effect on brain. Alcohol Res Health 1993;24:559-61.
22. NIH News ReleaseLargest ever comorbidity study reports prevalence and co-occurrence
of alcohol, drug, mood and anxiety disorders. Available at https://www.niaaa.nih.gov/news-
events/news-releases/largest-ever-comorbidity-study-reports-prevalence-and-co-occurrence.
Accessed on 20/08/16.
23. Davies M. The role of GABAA receptors in mediating the effects of alcohol in the central
nervous system. J Psychiatry Neurosci 2003;28:263-73.
24. Justin SR, Karyn B, John KB, Deborah AF, John CC. Evaluation of a simple model of ethanol
drinking to intoxication in C57BL/6J mice. Physiol Behav 2004;84:53-63.
25. Bansal P, Banerjee S. Effect of withania somnifera and shilajit on alcohol addiction in mice.
Pharmacogn Mag 2016;12:(Suppl 2)S121-8.
26. Julia AC, Christopher LC. GABA-A receptor modulation of the rewarding and aversive effects
of ethanol. Alcohol Alcoholism 2002;26:131-43.
27. Agarwal P, Sharma B, Fatima A, Jain SK. An update on Ayurvedic herb Convolvulus pluricaulis
Choisy. Asian Pac J Trop Biomed 2014;4:245-52.
28. Adinoff B, Kramer GL, Petty F. Levels of gamma aminobutyric acid in cerebrospinal uid and
plasma during alcohol withdrawal. Psychiatry Res 1995;59:137-44.
29. Kumar S, Porcu P, Werner DF, Matthews DB, Diaz-Granados JL, Helfand RS, et al. The role
of GABAA receptors in the acute and chronic effects of ethanol: a decade of progress.
Psychopharmacology 2009;205:529.
30. Indurwade NH, Biyani KR. Evaluation of comparative and combined depressive effect of
Brahmi, Shankhpushpi and Jatamansi in mice. Indian J Med Sci 2000;54:339-41.
31. Hetal A, Vyas HA, Harisha CR, Shukla VJ. A comparative pharmacognostic and phytochemical
study of Shankhpushpi. IJRPB 2011;2:1457-60.
the GABAA receptor have been shown to reduce alcohol consumption in
several alcohol-preferring mice.[21] Various phytoconstituents identied
from the aerial parts of C. pluricaulisy Choisy may act as GABAA agonist;
this may be attributed to its CNS-depressant actions.[30,31]
CONCLUSION
Hence, in the present study, we report anti-addictive potential of
shankhpushpi churna in alcohol addiction in mice. It not only reversed
ethanol withdrawal anxiety but also decreased chronic alcohol
consumption in these animals in a GABAA receptor-dependent manner.
Financial support and sponsorship
Nil.
Conicts of interest
ere are no conicts of interest.
REFERENCES
1. Drug free world available at http://www.medicalnewstoday.com/ info/addiction/. Accessed
on 20/08/16.
2. Drug abuse vectors available at www.vectorstock.com accessed on 20/08/16.
3. Pallensen S, Lorvik I, Bu EH, Molde H. An exploratory study investigating the effects of
treatment manual for addiction. Psychol Rep 2015;117:490-5.
4. Nicole MA, Pedro RB, Artley GH. Evidence for sugar addiction: behavioral and neurochemical
effects of intermittent, excessive sugar intake. Neurosci Biobehav Rev 2008;32:20-39.
5. Vengeliene V, Bilbao A, Molander A. Neuropharmacology of alcohol addiction. Br J Pharmacol
2008;154:299-15.
6. Fard MT, Arulselvan P, Karthivashan G, Adam SK, Fakurazi S. Bioactive extract from
Moringa oleifera inhibits the pro-inammatory mediators in lipopolysaccharide stimulated
macrophages. Pharmacogn Mag 2015;11:(Suppl 4)S556-63.
7. Sethiya NK, Mishra SH. Review on ethnomedicinal uses and phytopharmacology of memory
boosting herb Convolvulus pluricauli Choisy. Aust J Med Herb 2010;22:19-25.
8. Chulet R, Pradhan P. A review on rasayana. Pharmacogn Rev 2009;3:229-34.
9. Kulkarni R, Girish KJ, Kumar A. Nootropic herbs (Medhya Rasayana) in Ayurveda: an update.
Pharmacogn Rev 2012;6:147-53.
10. Siddiqui NA, Ahmad N, Musthaq N, Chattopadhyaya I, Kumria R, Gupta S. Neuropharmacological
prole of extracts of aerial parts of Convolvulus pluricaulis Choisy in mice model. Open
Neurol J 2011;8:11-4.
11. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkowa ND. Ethanol self-administration
and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1
receptors. Behav Brain Res 2005;164:206-13.
ABOUT AUTHOR
Dr. Sugato Banerjee, is Assistant Professor at Department of
Pharmaceutical Sciences and Technology, BIT, Mesra, Ranchi. His research
interests include screening of natural compounds with anti-addictive
potential and to study the molecular mechanisms involved in the process.
Sugato Banerjee
... It significantly showed reduced motor activity [16] . Whole plant Swiss albino mice Dried powder 100mg/kg 200mg/kg 10 days Shankhpushpi was able to reduced alcoholic withdrawal anxiety, and also increased the cortical hippocampal GABA level [17] . ...
... From table 1, Shankhpushpi churan (powder) was studied on alcoholic addictive mice for its antiaddictive behaviour. It showed the effective result on Cortico-hippocampal GABA levels and reported the antiaddictive potential [17] . ...
Article
Full-text available
Shankhpushpi is a plant and known as best brain tonic medicine which is classified under four Medhya Rasayana by Acharya Charaka. It is also included as main ingredient in many herbal extractives or decoction-based brain tonics or memory boosting formulations. Various Ayurvedacharya have named it as manglayakusuma, ksheerpushpi, medhya etc. Shankhpushi is also comes under convolvulacea family indicated as Convolvulus pluricaulis. The Charaka Samhita, which is an ancient book of Ayurveda described the use of paste (kalka) as Medhya Rasayana. There are so many experimental, pharmacological, clinical studies done on Convolvulus pluricaulis revealed the promising results as neuroprotective, memory enhancer, and antianxiety properties. The studies analysed its chemical composition like convolidine, convolvine, confoline etc. and may help to stimulate the brain activities. In addition, the studies have shown other properties like diuretic, antioxidant, hypolipidemic, hypotensive, antiulcer, antipyretic which helps to manage the various disorders. The various dosage forms like powder, paste, syrup is prepared by using whole plant or different parts of plant as indicated in classical texts. The present review study on Shankhpushpi basically focused on the experimental or clinical studies done in the management of various ailments.
... The effect of churna of shankhpushpi was measured on ethanol withdrawal anxiety in mice model using elevated plus maze. Results showed that shankhpushpi churna reversed ethanol withdrawal anxiety and also decreased chronic alcohol consumption in these mice in a GABA receptor-dependent manner [86]. ...
Article
Full-text available
India is enriched in a diversity of plants since past times. Herbal plants are indigenous and very potent that consider a gift of nature. Shankhpushpi (Convolvulus pluricaulis) is known as a Medhya (brain tonic) Rasayana in the Indian traditional system. The medicinal herb is considered to enhance certain aspects related to intellect and memory improvement. Shankhpushpi is a Sanskrit word that means "the plant with flowers shaped like a conch. It is a perennial herb which seems like morning glory. The shankha is one of Lord Shiva's sacred instruments. It consists of various phytochemical constituents mainly in the form of proteins, amino acids and the alkaloids convolvine. Many types of research have been done on the Convolvulus pluricaulis plant and showed various therapeutic and pharmacological activities. It includes nootropic activity, antidepressant, antistress, anxiolytic, antioxidant, antidiabetic, cardiovascular activity and many others. Thus this medicinal plant is playing a vital role in the medical field. The present review is a summary of the phytomedicinal importance of Convolvulus pluricaulis in the traditional medicinal system as well as the modern system. Keywords: Convolvulus pluricaulis, Shankhpushpi, Nootropic, Ayurveda, Alcohol
... No data Antioxidative (183,184); receptors (185,186); other (184,(187)(188)(189)(190) No data Nardostachys grandiflora D.C.* (181) (component of Banphool oil (182) females than males (Table 1). There were no clear associations with age or household consumption. ...
Article
Full-text available
Background In Nepal, traditional treatment using medicinal plants is popular. Whereas medication-overuse headache is, by definition, caused by excessive use of acute headache medication, we hypothesized that medicinal plants, being pharmacologically active, were as likely a cause. Methods We used data from a cross-sectional, nationwide population-based study, which enquired into headache and use of medicinal plants and allopathic medications. We searched the literature for pharmacodynamic actions of the medicinal plants. Results Of 2100 participants, 1794 (85.4%) reported headache in the preceding year; 161 (7.7%) reported headache on ≥15 days/month, of whom 28 (17.4%) had used medicinal plants and 117 (72.7%) allopathic medication(s). Of 46 with probable medication-overuse headache, 87.0% (40/46) were using allopathic medication(s) and 13.0% (6/46) medicinal plants, a ratio of 6.7:1, higher than the overall ratio among those with headache of 4.9:1 (912/185). Of 60 plant species identified, 49 were pharmacodynamically active on the central nervous system, with various effects of likely relevance in medication-overuse headache causation. Conclusions MPs are potentially a cause of medication-overuse headache, and not to be seen as innocent in this regard. Numbers presumptively affected in Nepal are low but not negligible. This pioneering project provides a starting point for further research to provide needed guidance on use of medicinal plants for headache.
... However, administration with GABA A blocker to animals followed by Shankhpushpi failed to show a decrease in ethanol and an increase in water intake till day 30. These findings also suggested that Shankhpushpi prevented chronic ethanol intake and showed antiaddictive potential, which may be mediated by GABA A receptors (Heba et al., 2017). ...
Chapter
Full-text available
Globally, neurologic and mental disorders are severe health challenges. They are particularly common in developing countries, in which the cultural aspects and poor or limited healthcare facilities make it more important to use traditional medicines. Neurological disorders are caused by a dysfunction in part of the nervous system or brain, resulting in physical and/or psychological symptoms. They are generally classified according to the location, cause, and type of dysfunction, and usually described as central and/or peripheral nervous system disorders. They are congenital, acquired, and idiopathic (unknown cause). Globally, neurological disorders are the main cause of mortality and constitute about 12% of total deaths. Some examples of neurological disorders are Alzheimer’s and other dementias, multiple sclerosis, Parkinson’s disease, cerebrovascular disease, migraine, neuroinfections, neurological injuries, nutritional deficiencies, neuropathies, tetanus, poliomyelitis, meningitis, Japanese encephalitis, epilepsy, etc. In lower-/middle-income countries, neurological disorders constitute about 16.8% of total deaths, while they account for 13.2% of total deaths in economically strong countries. According to an estimation from 2005, among the neurologic disorders, Alzheimer’s and other dementias caused about 2.84%, 0.46%, 0.41%, and 0.34% of the total deaths in high, upper-middle, low, and lower-middle income countries, respectively, in 2005.
Article
Research area of herbal psychopharmacology has been increased in this era. It is demand of the era to have comprehensive review of preclinical studies of Ayurveda herbal drugs as antidepressant, anxiolytic, and hypnotic psychopharmacology. On the basis of these findings, further clinical uses as well as better understanding of its mode of action and dosage form can be planned. In this review, search engines such as Ayush Portal, PubMed, DHARA, Research Gate, Scopus, AYU, Google Scholar, Academia, and Google were used to find out widely used psychotropic herbal medicines (last 20 years). A review was conducted to determine mechanisms of action of those drugs, in addition to a scientific review of preclinical trials for the treatment of most common psychiatric clinical conditions, i.e., anxiety and depression. Specific prominence was given to most apparent herbal medicines. Neurochemical as well as epigenetic activities were evident by results of individual herbal medicines in this review. Some drugs were found to be more effective in psychotropic activity, i.e., Kava ( Piper methysticum G. Forst.) and Klamath Weed ( Hypericum perforatum L.) for anxiety and depression disorders, respectively. However, because many researches have not been produced, caution should be exercised when interpreting the findings.
Article
C. pluricaulis Choisy (C. pluricaulis), a perennial herb aka C. microphyllus Sieb. and C. Prostratus Forsk. is being used as a traditional folk medicine for a variety of ailments. In this article, we collected information about C. pluricaulis through electronic search using PubMed, SciFinder, Google Scholar, and Web of Science as well as network pharmacology is done. This comprehensive review sheds light on the plant profile, phytochemistry, neuropharmacological, and toxicological data of C. pluricaulis. The crude herb and its metabolites have exhibited a wide range of in vitro and in vivo neuropharmacological effects, including memory enhancement, anxiolytic, tranquilizing, anti-depressant, anti-stress, neurodegenerative, anti-inflammatory, anti-oxidant, analgesic, sedative, anti-convulsant, and Alzheimer's disease-reversing effects. Network pharmacology results indicate that compounds from C. pluricaulis interact with various proteins, neuro synapses, signaling pathways, and serotonergic synapse which plays a crucial role in neurotransmission, Alzheimer’s disease, long-term depression, addictions to alcohol, cognitive disorders, psychological conditions, and increasing serotonin concentration in synapses.
Article
Full-text available
Alcohol Use Disorder (AUD) is a devastating disease with branching consequences that can affect one’s physical health, psychology, relationships, and finances. The etiology of AUD is as equally complicated as it is elusive, stemming from the inter- and intra-actions of a person’s genetics and environment. Instead of this, only three medications have been approved by the US Food and Drug Administration (FDA) to treat AUD: Disulfiram, naltrexone, and acamprosate. Additionally, clinicians often prescribe off-label medications such as nalmefene, varenicline, gabapentin, topiramate, zonisamide, baclofen, ondansetron, levetiracetam, quetiapine, aripiprazole, and selective serotonin reuptake inhibitors (SSRIs) in the treatment of patients with AUD. However, traditional pharmacological drug therapies possess restrictions in indications and outcomes that may limit their usefulness. Acknowledging this shortcoming has opened discussion of exploring alternative avenues of pharmacological treatments, with emphasis on the role of East Asian medicine and its efficacy in the treatment of AUD. In this review article, we aim to highlight the potential applications and mechanisms of commonly utilized herbal preparations as well as other non-Western alternative remedies in the treatment of AUD.
Article
Brain and neuronal circuits constitute the most complex organ networks in human body. They not only control and coordinate functions of all other organs, but also represent one of the most-affected systems with stress, lifestyle and age. With global increase in aging populations, these neuropathologies have emerged as major concern for maintaining quality of life. Recent era has witnessed a surge in nutritional remediation of brain dysfunctions primarily by “nutraceuticals” that refer to functional foods and supplements with pharmacological potential. Specific dietary patterns with a balanced intake of carbohydrates, fatty acids, vitamins and micronutrients have also been ascertained to promote brain health. Dietary herbs and their phytochemicals with wide range of biological and pharmacological activities and minimal adverse effects have gained remarkable attention as neuro-nutraceuticals. Neuro-nutraceutical potentials of herbs are often expressed as effects on cognitive response, circadian rhythm, neuromodulatory, antioxidant and anti-inflammatory activities that are mediated by effects on gene expression, epigenetics, protein synthesis along with their turnover and metabolic pathways. Epidemiological and experimental evidence have implicated enormous applications of herbal supplementation in neurodegenerative and psychiatric disorders. The present review highlights the identification, experimental evidence and applications of some herbs including Bacopa monniera, Withania somnifera, Curcuma longa, Helicteres angustifolia, Undaria pinnatifida, Haematococcus pluvialis, and Vitis vinifera, as neuro-nutraceuticals.
Chapter
Depression is a heterogeneous mood disorder characterized by a persistent feeling of sadness, loss of interest in daily activities. Many researchers implicate mechanism, which includes alterations of the serotonergic, dopaminergic, glutaminergic, and noradrenergic pathway. Altered KEAP1-Nrf2 pathway is a newly proposed mechanism for the pathophysiology of depression. In addition to this increased inflammation, neural apoptosis, and neuroplasticity, HPA axis abnormalities and vascular changes are proposed mechanism. Currently available allopathic drugs have been associated with several side effects. Hence, an alternative is required apart from these antidepressants. Herbal medicines prove to be a potential replacement for this. Traditionally, over 25,000 plant-based effective formulations are being used by doctors and also at home. Convolvulus pluricaulis (Shankhpushpi, Convolvulaceae) is well-known ethnopharmacologically as a brain tonic, which is also gaining a lot of importance due to its high potency and low toxicity. This chapter deals with phytochemistry and pharmacology of C. pluricaulis on depression.
Article
Full-text available
Background: Alcohol addiction is a social problem leading to both loss of health and economic prosperity among addicted individuals. Common properties of anti-addictive compounds include anti-anxiety, anticonvulsants, anti-depressant, and nootropic actions primarily through modulation of gamma-aminobutyric acid (GABA) and serotonergic systems. Objective: Here, we screen ashwagandha and shilajit known ethnopharmacologically as nervine tonic and adaptogenic herbs for possible anti-addictive potential. Materials and Methods: Effect of ashwagandha churna and shilajit was measured on ethanol withdrawal anxiety using elevated plus maze. Role of ashwagandha and shilajit on chronic ethanol consumption (21 days) was measured using two bottle choice protocol of voluntary drinking. We also measured the effect of the above herbs on corticohippocampal GABA, dopamine, and serotonin levels. Results: Both ashwagandha and shilajit were found to reduce alcohol withdrawal anxiety in a dose-dependent manner. These herbs alone or in combination also decreased ethanol intake and increased water intake significantly after 21 days of chronic administration. Chronic administration of ashwagandha was found to significantly increase GABA and serotonin levels whereas shilajit altered cortico-hippocampal dopamine in mice. Conclusion: These central nervous system active herbs alone or in combination reduced both alcohol dependence and withdrawal thus showing promising anti-addictive potential. SUMMARY Withinia Somnifera alone and in combination with Shilajeet prevented ethanol withdrawal and alcohol addiction Abbreviations used: GABA: Gama aminobutyric acid, CNS: Central Nervous System, CPP:Condition place preference, DA: Dopamine, 5-HT: 5-hydroxytryptamine, NMDA:N-methyl-D-aspartate Sugato Banerjee
Article
Full-text available
Background: Alcohol addiction is a social problem leading to both loss of health and economic prosperity among addicted individuals. Common properties of anti‑addictive compounds include anti‑anxiety, anticonvulsants, anti‑depressant, and nootropic actions primarily through modulation of gamma‑aminobutyric acid (GABA) and serotonergic systems. Objective: Here, we screen ashwagandha and shilajit known ethnopharmacologically as nervine tonic and adaptogenic herbs for possible anti‑addictive potential. Materials and Methods: Effect of ashwagandha churna and shilajit was measured on ethanol withdrawal anxiety using elevated plus maze. Role of ashwagandha and shilajit on chronic ethanol consumption (21 days) was measured using two bottle choice protocol of voluntary drinking. We also measured the effect of the above herbs on corticohippocampal GABA, dopamine, and serotonin levels. Results: Both ashwagandha and shilajit were found to reduce alcohol withdrawal anxiety in a dose‑dependent manner. These herbs alone or in combination also decreased ethanol intake and increased water intake significantly after 21 days of chronic administration. Chronic administration of ashwagandha was found to significantly increase GABA and serotonin levels whereas shilajit altered cortico‑hippocampal dopamine in mice. Conclusion: These central nervous system active herbs alone or in combination reduced both alcohol dependence and withdrawal thus showing promising anti‑addictive potential.
Article
Full-text available
Introduction: Inflammation is a well-known physiological response to protect the body against infection and restore tissue injury. Nevertheless, the chronic inflammation can trigger various inflammatory associated diseases/disorder. Moringa oleifera is a widely grown plant in most tropical countries and it has been recognized traditionally for several medicinal benefits. Objectives: The objective of this study was to investigate the anti-inflammatory properties of M. oleifera extract on lipopolysaccharide (LPS) - stimulated macrophages. Materials and methods: The anti-inflammatory effect of M. oleifera hydroethanolic bioactive leaves extracts was evaluated by assessing the inhibition of nitric oxide (NO) production during Griess reaction and the expression of pro-inflammatory mediators in macrophages. Results: Interestingly, we found that M. oleifera hydroethanolic bioactive leaves extract significantly inhibited the secretion of NO production and other inflammatory markers such as prostaglandin E2, tumor necrosis factor alpha, interleukin (IL)-6, and IL-1β. Meanwhile, the bioactive extract has induced the production of IL-10 in a dose-dependent manner. In addition, M. oleifera hydroethanolic bioactive leaves extract effectively suppressed the protein expression of inflammatory markers inducible NO synthase, cyclooxygenase-2, and nuclear factor kappa-light-chain-enhancer of activated B-cells p65 in LPS-induced RAW264.7 macrophages in a dose-dependent manner. Conclusion: These findings support the traditional use of M. oleifera plant as an effective treatment for inflammation associated diseases/disorders. Summary: Hydroethanolic extracts of Moringa oleifera effectively inhibit the NO production in LPS induced inflammatory model.M. oleifera crude extracts successfully modulate the production of pro-inflammatory mediators in LPS stimulated macrophages.M. oleifera extracts suppressed the expression of inflammatory mediators in LPS stimulated macrophages.
Article
Full-text available
-This study investigated the effects of a manualized therapy for video game addiction in 12 males, ages 14-18 yr. The manual was based on cognitive-behavioral therapy, short-term strategic family therapy, solution-focused therapy, and motivational interviewing. Treatment response was reported by the patients, their mothers, and the therapists. The patients reported moderate (but statistically non-significant) improvement from pre- to post-treatment. The mothers, however, reported large effects and statistically significant improvement from pre- to post-treatment. The therapists reported marked or moderate treatment response in six of the 12 patients. The ratings of change by mothers converged well with the views of change of both the patients and therapists, whereas the convergence of views on change between the two latter sources was far lower.
Article
Full-text available
The plant of Convolvulus pluricaulis Choisy was found to be used by different traditional systems and folklore for the treatment of various disorders. The aim of the present study was to investigate the neuropharmacological activity of various extracts of Convolvulus pluricaulis Choisy in albino mice. The animal behavior was evaluated by locomotor activity, tremors activity, sleep inducing model and anxiolytic activity using standard procedures in experimental animal models. The results revealed that ethanolic and aqueous extract showed promising results in terms of statistical manner when compared with control group. In conclusion, this plant exhibits neuorpharmacological activity in tested animals.
Article
Full-text available
Convolvulus pluricaulis Choisy (C. pluricaulis) is a perennial herb that seems like morning glory. All parts of the herb are known to possess therapeutic benefits. The plant is used locally in Indian and Chinese medicine to cure various diseases. It is used in Ayurvedic formulation for chronic cough, sleeplessness, epilepsy, hallucinations, anxiety etc. Based on the comprehensive review of plant profile, pharmacognosy, phytochemistry, pharmacological and toxicological data on the C. pluricaulis, there will be more opportunities for the future research and development on the herb C. pluricaulis. Information on the C. pluricaulis was collected via electronic search (using Pub Med, SciFinder, Google Scholar and Web of Science) and library search for articles published in peer-reviewed journals. Furthermore, information also was obtained from some local books on ethnopharmacology. This paper covers the literature, primarily pharmacological, from 1985 to the end of 2012. The C. pluricaulis is an important indigenous medicine, which has a long medicinal application for liver disease, epileptic disease, microbial disease, cytotoxic and viral diseases, central nervous system (CNS) disease in Ayurvedic medicine, traditional Chinese medicine and other indigenous medical systems. The isolated metabolites and crude extract have exhibited a wide of in vitro and in vivo pharmacological effect, including CNS depression, anxiolytic, tranquillizing, antidepressant, antistress, neurodegenerative, antiamnesic, antioxidant, hypolipidemic, immunomodulatory, analgesic, antifungal, antibacterial, antidiabetic, antiulcer, anticatatonic, and cardiovascular activity. A chemical study of this plant was then initiated, which led to the isolation of carbohydrats, proteins, alkaloids, fatty acids, steroids, coumarins, flavanoids, and glycosides as active chemicals that bring about its biological effects. A series of pharmacognostical studies of this plant show that it is a herb, its stem and leaves are hairy, more over it has two types of stomata, anisocytic and paracytic. A herb, C. pluricaulis has emerged as a good source of the traditional medicine for the treatment of liver disease, epileptic disease, microbial disease, cytotoxic and viral diseases, and CNS disease. Pharmacological results have validated the use of this species in traditional medicine. All the parts of the herb are known to possess therapeutic benefits. Expansion of research materials would provide more opportunities for the discovery of new bioactive principles from C. pluricaulis.
Article
Full-text available
Convolvulus pluricaulis Choisy: a rasayana drug which is mainly advocated for use in mental stimulation and rejuvenation therapy. It is known as Shankhpushpi by Ayurvedic practitioners in ancient systems of Indian medicine as it was a prominent memory improving drug, a psychostimulant and tranquiliser in traditional Indian medicine. The plant contains several alkaloids, flavanoids and coumarins as active chemicals that bring about its biological effects. Little human research has been published in the Western medical literature regarding this plant. Preclinical (in vivo and vitro) investigations have demonstrated nootropic, anxiolytic, tranquillising, antidepressant, antistress, neurodegenerative, antiamnesic, antioxidant, hypolipidemic, immunomodulatory, anti- inflammatory, analgesic, antimicrobial, insecticidal, antifungal, antibacterial, antidiabetic, antiulcer, anticatatonic and cardiovascular activity. Clinical studies of its polyherbal formulation justified its potential for the ancient claim of brain tonic. The present review is an attempt to compile information on various ethnomedical aspects of Convolvulus pluricaulis, shankhpushpi of Indian traditional medicine.
Article
Full-text available
Previous studies have shown that both 3-amino-1,2,4-triazole (AT), which inhibits metabolism of ethanol (EtOH) to acetaldehyde by inhibiting catalase, and D-penicillamine (D-P), an acetaldehyde-sequestering agent, modulate EtOH-conditioned place preference (CPP) in male albino Swiss (IOPS Orl) mice. These studies followed a reference-dose-like procedure, which involves comparing cues that have both been paired with EtOH. However, the role of EtOH-derived acetaldehyde has not been examined using a standard CPP method, and efficacy of these treatments could be different under the two circumstances. In the present investigation, we manipulated the strength of CPP across five separate studies and evaluated the effect of D-P and AT on EtOH-induced CPP following a standard unbiased CPP procedure. Mice received pairings with vehicle-saline injections with one cue and, alternatively, with AT- and D-P-EtOH with another cue. Our studies indicate that AT and D-P only disrupt CPP induced by EtOH in mice when the number of conditioning sessions and the dose of EtOH are low. These findings suggest that acquisition of EtOH-induced CPP may depend on the levels of acetaldehyde available during memory acquisition and the strength of the memory. Therefore, we propose that, at least when the memory processes are labile, brain acetaldehyde could participate in the formation of Pavlovian learning elicited by EtOH.
Article
Full-text available
Cognitive deficits that present with many of neuropsychiatric conditions and/or alone as developmental deficit demand use of nootropics to boost cognitive abilities. Recently there is a tremendous urge to explore medicinal plants globally for improving cognitive function owing to their less adverse effects. Ayurveda provides a list of herbs known for nootropic activity as well as their multi-dimensional utility in various conditions. Present paper is a review to update knowledge on pharmacological properties, major chemical constituents, therapeutic actions, preclinical studies, safety and possible mode of action of the selected herbs from ayurvedic pharmacopoeia. Concurrently, it opens up for further research and standardization on nootropic herbs.
Article
Rasayana is one of the eight clinical specialities of classical Ayurveda. Rasayana replenish the vital fluids of our body, thus keeping us away from diseases. The rasayana therapy enhance the qualities of rasa, enriches it with nutrients so one can attains longevity, memory, intelligence, freedom from disorder, youthfulness, excellence of luster, complexion and voice, optimum development of physique and sense organs, mastery over phonetics and brilliance. Taking rasayana is helpful to increase the immunity of the person to keep him away from disease and also reverses the disease process and prevents the re-occurrence. The Rasayanas are rejuvenators, nutritional supplements and possess strong antioxidant activity. They also have antagonistic actions on the oxidative stressors, which give rise to the formation of different free radicals. Ocimum sanctum, Tinospora cordifolia, Emblica officinalis, Convolvulus pluricaulis, Centella asiatica, Bacopa monniera, Withania somnifera, Triphala rasayana, Chyawanprash, Brahma rasayana are very important rasayanas which are described in ayurveda and proved by new researches.